Aspirin use does not appear to reduce the risk of mortality associated with prostate cancer, according to research published in the April issue of The Journal of Urology.
READ FULL ARTICLE
From Medical Express
Aspirin not associated with decreased prostate cancer-associated mortality
the Oncology Nurse Advisor take:
According to a recent study published in The Journal of Urology, researchers from Jewish General Hospital in Montreal, Quebec, Canada, have found that aspirin use does not decrease the risk of mortality associated with prostate cancer.
For the study, researchers followed a cohort of 11,779 men diagnosed with nonmetastatic prostate cancer between 1998 and 2009. Patients were followed until 2012 in order to assess associations between aspirin use and both prostate and all-cause mortality.
Results showed that a median follow-up of 5.4 years, aspirin use after cancer diagnosis was associated with increased risks of prostate cancer mortality (HR = 1.46; 95% CI: 1.26-1.50).
Researchers also found that the risk of prostate cancer-associated mortality was increased in patients who started using aspirin after they were were diagnosed with cancer (HR = 1.84; 95% CI: 1.59-2.12), whereas those who were using aspirin before diagnosis did not have an increased risk of cancer-associated mortality (HR = 0.97; 95% CI: 0.81-1.16.
The study showed similar risks for all cause-mortality and post- and pre-diagnostic aspirin use.
